Bamboat Zubin M, Tang Laura H, Vinuela Eduardo, Kuk Deborah, Gonen Mithat, Shah Manish A, Brennan Murray F, Coit Daniel G, Strong Vivian E
Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2014 May;21(5):1678-85. doi: 10.1245/s10434-013-3466-8. Epub 2014 Jan 7.
The prognosis of signet ring cell (SRC) gastric adenocarcinoma is regarded as poor, although studies addressing outcomes in relation to non-SRC tumors are conflicting. Our objective was to compare the survival of SRC tumors with stage-matched intestinal-type tumors in a cohort of Western patients.
Review of a prospectively maintained database identified 569 patients undergoing curative resection (R0) from 1990 to 2009. Patients were divided into three histologic groups on the basis of the Lauren classification: SRC (n = 210), intestinal well- or moderately differentiated (WMD, n = 242) disease, and intestinal poorly differentiated (PD, n = 117) disease. Patient demographics, clinicopathologic features, and postoperative outcomes were determined. Stage-stratified disease-specific mortality was calculated and multivariate analysis performed.
When compared with WMD and PD tumors, SRC tumors were associated with younger age (63 years SRC vs. 71 years WMD and 72 years PD, p < 0.0001) and with female sex (58 % SRC vs. 40 % WMD and 40 % PD, p = 0.0003). Median follow-up was 115 months. Patients with stage Ia SRC lesions had a better 5-year disease-specific mortality compared with stage-matched intestinal-type tumors (0 % SRC vs. 8 % WMD and 24 % PD, p = 0.001). In contrast, SRC patients with stage III disease fared significantly worse (78 % SRC vs. 54 % WMD and 72 % PD, p = 0.001). On multivariate analysis, the risk of death from gastric cancer comparing all three groups was lowest for SRC in stage I and highest for SRC in stage III disease (stage III hazard ratio: SRC 1 vs. 0.47 WMD and 0.85 PD).
When compared with intestinal-type tumors, SRC tumors at early stages are not necessarily associated with poor outcomes.
尽管有关印戒细胞(SRC)胃腺癌与非SRC肿瘤相关结局的研究结果相互矛盾,但一般认为SRC胃腺癌的预后较差。我们的目的是比较一组西方患者中SRC肿瘤与分期匹配的肠型肿瘤的生存率。
回顾一个前瞻性维护的数据库,确定了1990年至2009年间接受根治性切除(R0)的569例患者。根据劳伦分类法,将患者分为三个组织学组:SRC(n = 210)、肠型高分化或中分化(WMD,n = 242)疾病和肠型低分化(PD,n = 117)疾病。确定患者的人口统计学、临床病理特征和术后结局。计算分期分层的疾病特异性死亡率并进行多变量分析。
与WMD和PD肿瘤相比,SRC肿瘤患者年龄较轻(SRC为63岁,WMD为71岁,PD为72岁,p < 0.0001)且女性居多(SRC为58%,WMD为40%,PD为40%,p = 0.0003)。中位随访时间为115个月。Ia期SRC病变患者的5年疾病特异性死亡率优于分期匹配的肠型肿瘤(SRC为0%,WMD为8%,PD为24%,p = 0.001)。相比之下,III期SRC患者的情况明显更差(SRC为78%,WMD为54%,PD为72%,p = 0.001)。多变量分析显示,三组中胃癌死亡风险在I期SRC最低,在III期SRC最高(III期风险比:SRC为1,WMD为0.47,PD为0.85)。
与肠型肿瘤相比,早期SRC肿瘤不一定预后不良。